John Pfeiffer is a seasoned Enterprise Infrastructure Consultant at a leading Global Pharmaceutical Company, where he leverages over 20 years of extensive experience to drive transformative technology initiatives. In his current role, John specializes in the migration of on-premise services to Microsoft Azure AD and...
John Pfeiffer is a seasoned Enterprise Infrastructure Consultant at a leading Global Pharmaceutical Company, where he leverages over 20 years of extensive experience to drive transformative technology initiatives. In his current role, John specializes in the migration of on-premise services to Microsoft Azure AD and Office 365, ensuring seamless transitions that enhance operational efficiency and security. His expertise in Azure Active Directory, Azure Security Center, and Azure Information Protection positions him as a pivotal resource in safeguarding sensitive data and managing identity and access management (IAM) protocols.
John is actively involved in key projects that include the upgrade of Pfizer’s Domain Controllers to Windows Server 2016, which is critical for maintaining robust security and compliance standards. He also plays a vital role in the migration of Active Directory servers and user provisioning to Office 365, facilitating the adoption of cloud-based collaboration tools such as Exchange Online, SharePoint, OneDrive, Outlook, and Teams. His proficiency in Azure Advanced Threat Protection and Microsoft Defender further enhances the company’s security posture, allowing for proactive threat detection and response.
In addition to his technical skills, John excels in solution architecture and role-based access control (RBAC), ensuring that the infrastructure not only meets current business needs but is also scalable for future growth. His comprehensive understanding of network administration and DNS management complements his work, enabling him to troubleshoot complex issues effectively. As a thought leader in enterprise infrastructure, John Pfeiffer continues to drive innovation and excellence within the pharmaceutical sector, making significant contributions to the company’s digital transformation journey.
